Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
You're talking about Ifenprodil, data 1st week of Dec.?.
The Plan Warrants shall include such anti-dilution provisions
which are standard for common stock purchase warrants of this type, with the anti-dilution to be
terminated upon the Reorganized Debtor’s consummating the listing of its common stock on the
NASDAQ Capital Markets or another senior exchange.
Yes, up to 300M initially is Possible.
Does Auctus want to take a company with contents thru Clinical Trials and create a possible Nasdaq stock as stated in the 8k or have to bust ass selling hard $.01s while killing the possible golden goose? ...GLTA...
Yes, I think PFE is taking their early data and applying for the EUA. Then whatever time to expedite COVID applications.?.
Politics probably wont hurt either. Will the US "preordered and paid for doses" be filled? When? Will it be 'transient' if the virus mutates?
It's still an expensive Vaccine with logistics issues. Not a therapeutic like Ifenprodil. Unfortunately plenty of patients with needs...JMHO...
Remdesivir is barely effective, per 'should we Rem patients' which followed . That sets a low bar for anything that Actually works. BigP does influence the USFDA, IMO. Data needs to be presented through the FDA, it may be faster but not less strict...GLTA...
Sorry for the dumb pun, OTC, butt, my point was Ifenprodil is easily scaled for large production and/or distribution by a company and it has a good safety record. Nyquil and Tylanol PM/C+F aren't sold to minors yet are dangerous, especially when overdone or with alcohol. They still sell billions of doses OTC though. There are lots of people that dont go to hospitals when sick or until it's too late with Covid. If Ifenprodil works... Could be big...
$20 for ten pills?
I suggest some long time longs have made the efforts to share their DD at everyone's benefit. Those efforts have brought many to invest in this company. Like the personas or not.
We are in the pack now but have a strong entrant still, with a distinct path of it's MOA..
Sure big waves from the BigPs about transient/expensive vaccines. Not our battle.
With limited effectiveness of known treatments like Rem as the standard, the anticipated signals from the Ifenprodil Covid Trial are hard to wait for. Some have had their boats loaded and maintained confidence and patience for a long time. This forum has maintained relative class and honesty throughout, IMO...
Ifenprodil is a simple pill that will be easily scaled for world wide use, IMO. No long infusion courses, no extreme costs or tough logistics. Maybe a Bayer or JJ can see the future and have the interest and capability. Basically an Over The Counter treatment, IMO.
My Prayers to all suffering from this and to the families. Now with the strong hope this will help rescue My USA from incompetent's obfuscations and those that didnt think a Mask and distancing would make a difference. Even with strict regulations with early successes like in SK and Japan, those not conforming have caused continued spreading of Covid...GLTA...
I know we have left as a sponsor of the SK trials due to early success there in fighting Covid. May 8 was supposed to be the start of that Trial. We'd all be rich already with August data from that and the world might have done better with Ifenprodil as a treatment.
Now they are having a 2nd stage of infections and are on the Moderna/Pfizer list for vaccines. Oh well.
Strange that the SK Trial is still listed as 'recruiting'.
Finally we will see Data on Ifenprodil with the International Covid Trial completing and a Data readout 1st week of December.
Time for Novatech to earn their pay in the IPF Trial, Bat Soup excuses. At least GDI has apparently done well here in the USA with enrollments.
Shoulda coulda woulda beens. ..GLTA...
https://cris.nih.go.kr/cris/en/search/basic_search.jsp
https://en.yna.co.kr/view/AEN20201117010100315?section=business/health
Vaccines have already been pre paid for by US taxpayer, even if it has only limited testing and may not work?.?
Plagiarized:
Vaccine has to be supplied to various countries via advanced purchase agreements... pre-arranged with companies to purchase the vaccines in advance of knowing if they worked
- Canada and USA are examples that have advanced purchase agreements.
- Each country wanting to use vaccine need to provide the data to the regulators
- FDA and Health Canada will look at those results and rest of the data
- rolling submissions have been carried out...
I missed some early butt I saw;
Dr Mark Williams was there and seemed to be strutting, not squirming. I liked his comment about logistics of some in Trial while "you can carry Ifenprodil in your pocket". Also mentioned Ifenprodil as a prophylactic's for higher risk population.?. Also possible Cancer uses for Ifenprodil.?. Focus is on getting current workload with the COVID Trial done.!.
Some slow down of enrollment (efforts) in Australia/NZ IPF but new site(s) planned.
I cant find a replay. Other's observations?
We're a small company with a Chance...GLTA...
Maybe one of the therapeutics in Every cocktail...
All Big Pharmas don't have a therapeutic, yet. It's safe.
This could scale world wide, fast, IMO...
Yea, that may come pretty fast with the relatively low outstanding shares, if the news deserves it. IMO too...
But I'll mainly stick around to find out what they DO with that 'bird in the hand'...Big Pharma is not doing real well in their results, so far...
My recent guesses stand. Other posts have shown the easy math and we all have crystal ball theories. CM surely has many possible plans covered as seen in the discussions on Videos...Good past calls with your $ here, IMO. W-B...GLTA...
Sure happy this management is so frugal with our investments and PP monies. 140M OS is miniscule compared to some competition to get this Drug through initial Trials.
They have also waited to present data until it would Not affect patients or further data. In Smoki's posted Video, CM says the Trial will be wrapped up by then.
Gathering Data from around the World, where some Trial Sites are located, may present some challenges and of course some sites will complete prior to others. Of course #2, this wide variety will make the data all that more accepted, IMO.
The next gathered data will follow in a couple weeks, possibly. BigPharma is shooting blanks so far compared to the NEEDS and $$$ thrown at this disease.
The three Arms of this Trial are open label but actual presentable Data will need to be documented in the proper formats for reviews after release of 'raw' data from the Trial Sites.
@ 140M OS, a Biggie can partner here cheap for quicker production and distribution of Ifenprodil ($1B+) or maybe buyout the 'Rights' for a couple $B and we will All be Very Happy.
Yes, I suggest we take BigP Shares if that's the offer. Yes, I suggest Royalties may also be a good path for AGN shareholders with up front Licensing fees.....
Other solutions to join the COVID fight are very expensive for patients, they may have long infusion courses and/or logistics and production issues when scaling up to the NEEDED amounts, Worldwide.
IFENPRODIL is an inexpensive, easily produced and proven safe PILL and we will soon Officially hear how well it worked. Obviously it passed Safety and Futility reviews, UNANAMOUSLY, already...
Hmmm, seen some Jarheads here, gota be brave to play here. 72grunt. Now I play 2 stocks with 2.6B os, well they might pass muster. But my Favorite is only 130M os, see this ID history. Supported actions brothers, no friendly fire...
The answer to RLF-100 storage question is the same basically. Keep it in a sub-zero until use time...
I bet that CEO wont be reelected, but he's got his $ and contracts for more. 50-Million doses in 2021 and maybe half sold to US. 2021 W-W production plans are huge, just like Remdesivir. I'll have my Bat Soup luke warmed by the sun please, extra flies.
It's not "no fault". There has been NO Leadership for My Country, forcing States to fight over resources, withholding Federal funds and equipment and NOT making any attempt to help schools be safe for education and America's Children, allowing Senate leaders and partisan issues to even close .Gov...A SICK response and demonstrated lack of ANY Effort or Thought...
God Bless OUR Troops and the Drs/Nurses that have Earned Veteran Status thru their Efforts. even without National Leadership...JMHFO...
My recent post's points were a 50% differential in the rating of patients recovery after treatment would be monumental compared to the current rates of success.
Big-Pharma is focusing on virs/mAbs/*vaccines.
At the recent NIH videocast, the FDA rep stressed their job to regulate and Not bend rules.
Repurposed drugs may make it to market sooner than others due to good past Safety records.
There is a huge market for Prevention and treatments of COVID and then the recovery from the resulting damages...GLTA...
There are several polls out showing less than 50% will take a vaccine as soon as it is available. Most have said that they would wait for Trials to move further or until people can see an obvious advantage to taking them like the yearly 'flu shots',
The Pfizer CEO said they will have a total of 50M doses in 2020 split Worldwide. Thats about 12M vaccinated in the US. 1B+ doses could be available by 2022. Cant find a price.
Of course some mAbs will be produced at their extreme high costs too. Rem will be around as it is being favored now as a SOC by the FDA. I still cant find info of any great success from Rem as compared to other SOC W/O Rem.
Doesnt 50% seem like a good base target for success?
Only a couple Drugs will be presenting data this year for Treatments and the EUA from the FDA that's needed here to start marketing. Both I know of are repurposed drugs with a Good Safety record. That puts them way ahead in this Race to be a contributor to the Fight against the effects of COVID.
I would say Prevention drugs/treatments/vaccines will be a next step but require huge populations to prove effectiveness and time to be accepted and produced for the general populations.
Billions of people may want a vaccine, eventually, and 50 Million were infected world wide so far.
Could sell the "investment" here as apparently is suggested others do. Then no worries about BRTX, W or W/O Q and history.
Lotta effort arguing with the few not just flipping the + or - $.001s. "WE"(?)...
It's a company emerging from BK with new patents, a financer for their Trial and dilution to pay for it all.
< video poker odds, possibly greater payout, no one is forced to play.
Shark liver oil was used in WW2 in plane engines as the best lubricant of the time and is the basis for WD40...LOL...
All Out@.53 but I'm watching to see about the IPO(?) and how RLF-100 IV does at the interim review and Inhaler news. Re-entry.
2;30 mins, "study will be completed by the time this interim data is released"...
One cant make mistakes if nothing is done or said or crystal balled...So...
Overall the PR showed high confidence. IMO.
With 3 arms of this Trial maybe an aggregate of 25 for each arm is the data pool...BUT...But [proved wrong already...
This PR is slanted toward the number of patients needed for the Phase 3 part of this Trial which was proposed at 642 total for 2b/3 combined. Very positive, IMO.
Collecting data from around the world will be strong evidence and probably a logistical challenge.
Also I like the words 'Phase 3 will start Immediately after Phase 2 data '.
I hope strong efforts are working toward full enrolment and complete Phase 2b asap.
Pfizer vaccine may have 50M doses produced in 2021. Already 50M Covid infections Worldwide with 7B population...and raising
They were talking about *mAbs - *virs combinations with other specific treatments as needed.
Ifenprodil has a good safety and interaction record so "I" think that wont be an issue. Plenty of DD discussed and there are links to lots of interesting stuff on this MB.
Low effectiveness by Rem seems to be the best game in town now and is SOC.
In the NIH videocast the FDA guy stated / stressed the need for complete Data and Trials for FDA considerations of eua-eap-limited use-trials---all approvals, AND completing later stage Trials for all.
...Rem was developed by Gilead in Wuhan China at the Wuhan Virologic inst while researching SArs ect. A theory of initial spread from/in Wuhan is Bat Soup.
Rem already has side affects.
Normal SOC was only improved 15% with Rem. Gilead $ and political pressure to do something seems to have influence on Rem use decisions, IMO.
This article from AGN shows NP120 with a lot of very high class competition. It is also interesting on what drugs were not included. End of 2020 readout for np120 is one of the first to results!
The NIH Video also talked about NDMA and cyclonite and actions to fight it. Rem is the SOC and new drugs need to be tested with it as a combo. Combinations of treatments and drugs are the future in the fight against COVID.
Vaccine talk was over my head but Trials and production for them will be important issues.
Minimal interactions and no long term safety issues were mentioned for Repurposed drugs' as past safety records will allow them to move to later Stage Trials and possible use quickly for specific indications.
Q? Are the sites where NP120 is being Trialed at using Rem as a SOC.?. One main concern brought up was will other drugs going to be conflicting with Rem which they are including as part of SOC?
US COVID cases raise to over 100K a day and world wide increases in infections are very concerning...GLTA...
PS...The NIH videocast will be reposted on their site soon so it can be watched again. It's 4 1/2 hrs long and I missed some. .
I cant find VIP drugs here and they were not discussed in the NIH Stream that I saw. NDMA / cyclonites were discussed.
NIH videocast will be up on their site asap. Great sources.
https://www.evaluate.com/vantage/articles/analysis/spotlight/scanning-horizon-future-covid-19-treatments
NIh discussion final comments of treatments, 'combinations of treatments are the most promising'.. mAbs discussions now. I'll try to post replay soon...
https://videocast.nih.gov/livew.asp?live=38975
So, it's not normal for a company to secure funding for a recently approved Clinical Trial that is based on new patents and to have this info all found in the 8k of a company that is emerging from BK,?, hmmmm. All that for way under a dime right now.?. So, maybe it is good news. hmmmm...GLTA...
Interesting post... So I guess having been granted these patents as you posted from the 8k, as well as now getting the trial funding also being in this 8k is Good news, right?
We all hope for a positive result on the EUAs. Adding patients seems to indicate nothing fast there.?. Moving forward at the Trials should be the Primary focus as success there will certainly make a common IPO a success. IMO.
Full Data from the combined 21 + @30 and @102 is now with the DSMC / FDA as reported by some and this is still a strong reason to invest or stay invested. IMO. Cant win or lose here if you dont play this game.
Prescient? dude? I didnt like the look @$.53 last week but didnt think this is where this would go so fast.
Delay in the Trials may be baked in now.?. I dont think there will be news on Trials, Data or IPO soonest. Need a prospectus. Do Gem/insiders have sufficient power to complete this/a deal and bring RLF into this IPO entity? RS Vote? RLF pays for R+D alone? Bat soup...
Strong science meets loose lips - DrJJ, too many hyped false starts, too many shares. Hope they are finally using the $30+M raised from GEM to get these Trials possibly Expedited! Not pay for his other company's IPO...
As spokesman and leadership roles for both companies , blame and or praise centers there. I want back in but wont 'chase' this down...GLTA... of
Given that the DSMC said to finish Trials and so far no EUA, the price $1.6B is fair. IMO, fwiw...
Rumors of processing the EUA and strong data are known. Yes, GEM has a big say and finances both and Wants a profit, asap, maybe already i$-ha$. RLF has $30+M on the books for those 400m shares to GEM.
So still we dont know how this will fit together thru approval(s?), delayed completions and readouts of IV and Inhaler Trials, production, sales (except profit splits when/if) and then distribution logistics and IPO of sister to NYSE BigPharma.
Question. What relevance is there between NRX101 and RLF100.
Mergers and reverse splits usually have a vote for approval by shareholders on US exchanges. However we may have seen that insiders and GEM control enough shares to dominate a quorum/vote.?.
The NYSE BigPharma will have a vote whether to allow the NRX/? IPO. Somehow RLF needs to be rolled into this new entity due to their development and costs for RLF-100 / VIP intellectual property and patents. Show us the CA$H, Dr JJ.**.
There will need to be a proxy, I hope. RLF shareholders should have a vote where our product and it's costs will be 'profitable' to whatever entity is really happening.
** Dr JJ being involved with both NRX and RLf will need to be clarified, especially as being the spokesperson for both companies...
Getting to be an OTC wizz. Like the rest of us, blo> bth> Nash> AGN, default brilliant.
Moving up from 2.6B-os+ IPO+ to a 1.9B-os /300B-AS.. Certainly them be flippers there. done that...
I'll hold AGN, IMO. Brilliant, Guinness Genius...GLTA...
I cant see why not if the Trial is concluding and that possibly Very strong Data is in DSMC / FDA. Dr JJ presenting for NRX or RLF or both.
It does Not become your prior efforts and respected posts to side step an opportunity to express realistic answers with how you address the Questions raised. You are taking this time and effort to post a sarcastic answer, sad, IMHO.
Several posters with posted links are a part of the impetus for these questions.
I can't see that happening because it's only 150 patients", AGN IS finishing Their COVID Phase2b Trial, that's the CURRENT plan. No pie in the sky pumping by THIS management. IMO...
But with 21 patients or even 102, some DSMC / FDA interventions are expected elsewhere. On an incomplete phase 2b. Hmmm. Posts there? or did they block/ban insolence..
Management here has caused these confusions. IMO.
I dont understand the NRX - IPO as related to RLF also. Fair questions and comments V*fit, IMO. Send it, as your message will go to the same area as Mine... We comment and do DD HERE because of the Gulf of non-info and twisted declarations compounding isssues from the entity NRX-RLF...JMHFO...GLTA...
DrJJ has referred to these Trials several times as Phase 3. Phase 2b is now expected to continue by the FDA until completion. Early data on 21 Eua + 102 patients from the 2b 144 (+21 for early viewing of data?) is being processed / Trial completed ? Dates for readouts and the Inhaler Trial have slid. Did I miss something?
I apparently am confused with these presented assumptions as to facts about 2b/3 Trials.
not specifically directed at you aGuy. Appreciate your input always though...